What is Denali Therapeutics Inc.'s G&A?

Denali Therapeutics Inc. (DNLI) reported G&A of $33.51M in Q1 2026.

How has Denali Therapeutics Inc.'s G&A changed year-over-year?

Denali Therapeutics Inc.'s G&A increased by 14.2% year-over-year, from $29.35M to $33.51M.

What is the long-term trend for Denali Therapeutics Inc.'s G&A?

Over 4 years (2021 to 2025), Denali Therapeutics Inc.'s G&A has grown at a 14.6% compound annual growth rate (CAGR), from $79.06M to $136.56M.

Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.

Denali Therapeutics Inc. DNLI G&A

G&A at other companies

Viking TherapeuticsVKTX

$13.98M-0.7%

Dyne Therapeutics, Inc.DYN

$24.39M+53.1%

Enliven TherapeuticsELVN

$7.14M+5.0%

Beam TherapeuticsBEAM

$34.43M+23.2%

Xenon PharmaceuticalsXENE

$23.82M+25.1%

Praxis Precision Medicines, Inc.PRAX

$27.87M+100%

Segments

By segment

See full

Therapeutics Segment$33.51M+14.2%

Other financials

Income statement

See full

Revenue-—

Operating income-$137.4M+5.6%

Net income-$128.4M+3.4%

EPS (diluted)-$0.69+11.5%

Balance sheet

See full

Cash & equivalents$390.7M+551%

Total debt$40.0M-22.3%

Total equity$926.1M-17.5%

Total assets$1.3B-0.4%

Cash flow

See full

Operating cash flow-$131.2M+0.2%

CapEx$2.5M-51.4%

Free cash flow-$133.7M+2.1%

Valuation

See full

Market cap$3.93B+54.2%

Profitability

See full

Operating margin-37,938%-37,986pp

Net margin-33,121.9%-33,159pp

FCF margin-31,736.3%-31,830pp

Returns & leverage

See full

Return on equity-49.6%+34.2pp

Debt / equity0×0.0×

Current ratio9.3×-0.3×

Where this comes from

Reported directly by Denali Therapeutics Inc. in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: Denali Therapeutics Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Denali Therapeutics Inc.'s g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Denali Therapeutics Inc.'s G&A?: Denali Therapeutics Inc. (DNLI) reported G&A of $33.51M in Q1 2026.
How has Denali Therapeutics Inc.'s G&A changed year-over-year?: Denali Therapeutics Inc.'s G&A increased by 14.2% year-over-year, from $29.35M to $33.51M.
What is the long-term trend for Denali Therapeutics Inc.'s G&A?: Over 4 years (2021 to 2025), Denali Therapeutics Inc.'s G&A has grown at a 14.6% compound annual growth rate (CAGR), from $79.06M to $136.56M.
What does G&A mean?: Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.